% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hoffmann:306257,
author = {C. Hoffmann$^*$ and H. Hautzel$^*$ and M. Wiesweg$^*$ and
D. Kersting$^*$ and N. Guberina$^*$ and C. Pöttgen$^*$ and
M. Metzenmacher$^*$ and M. Schuler$^*$ and T. Gauler$^*$ and
B. Höing$^*$ and C. Kürten$^*$ and F. Doerr$^*$ and S.
Bölükbas$^*$ and N. Baldes$^*$ and M. Opitz$^*$ and A.
Milosevic$^*$ and F. Nensa$^*$ and L. Umutlu$^*$ and F.
Funke$^*$ and W. P. Fendler$^*$ and K. Herrmann$^*$ and M.
Stuschke$^*$ and M. Guberina$^*$},
title = {[18{F}]{FDG}-{PET}/{CT}-based evaluation of tumor response
kinetics during induction chemotherapy and concurrent
radiochemotherapy in stage {II} - {III} small-cell lung
cancer.},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {nn},
issn = {1619-7070},
address = {Heidelberg [u.a.]},
publisher = {Springer-Verl.},
reportid = {DKFZ-2025-02486},
pages = {nn},
year = {2025},
note = {epub},
abstract = {Evaluation of interim-[18F]FDG-PET/CT as a prognostic tool
in limited disease small cell lung cancer (SCLC).We included
35 patients with limited disease SCLC from a prospective
institutional registry in this retrospective study. Patients
received induction chemotherapy (3-4 cycles) followed by
concurrent radiochemotherapy. Baseline [18F]FDG-PET/CT was
performed before or shortly after start of induction
chemotherapy, interim PET/CT was acquired during late
induction or concurrent chemoradiotherapy. Maximum
standardized uptake value (SUVmax), metabolic target volume
(MTV), and total lesion glycolysis values (TLG) were
determined. An exponential decay model with an asymptotic
offset was used to describe treatment response over time.
Deviations > 2 standard deviations (SD) above
model-predicted means after day 30 were considered poor
response. Progression-free survival (PFS) was analyzed.All
patients underwent twice-daily radiotherapy to a base dose
of 45 Gy. SUVmax showed greater inter-patient variability
than MTV. Poor treatment response was observed in $17\%,$
$31\%,$ or $14\%$ at the SUVmax, MTV and TLG endpoints.
Deviations > 2 SD from the model in SUVmax and TLG were
significantly associated with shorter PFS (p = 0.0003, p =
0.0014); MTV was not prognostic (p = 0.2630). Leave-one-out
cross-validation (LOOCV) could confirm the prognostic value
of the standardized residual SUVmax larger than 2 standard
deviations above model estimate as negative PFS predictor (p
= 0.0152, Fishers exact test).Our decay model enables the
characterization of [18F]FDG-PET/CT response parameters from
scans acquired at variable time points during induction
chemotherapy and at start of concurrent radiochemotherapy.
Poor SUVmax or TLG response was predictive of PFS.
Interim-[18F]FDG-PET/CT response may guide individualized
treatment adaptation.},
keywords = {Prognostic (Other) / Radiotherapy (Other) / Small cell lung
cancer (Other) / Treatment response (Other) /
[18F]FDG-PET/CT (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41247515},
doi = {10.1007/s00259-025-07658-5},
url = {https://inrepo02.dkfz.de/record/306257},
}